Exhibit 99.1 NEUEHEALTH REPORTS FIRST QUARTER 2024 RESULTS DORAL, Fla. (May 8, 2024) (BUSINESSWIRE) – NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE: NEUE), the value- driven healthcare company, today reported financial results for its First Quarter ended March 31, 2024. "We had a strong start to the year, continuing to advance our value-driven, consumer-centric care model as we build on our strong relationships with providers and payors to make high-quality healthcare more accessible and affordable ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Registrant's telephone number, including area code: (612) 238-1321 For the transition period from to Commission file number 001-40537 NEUEHEALTH, INC. (Exact Name of Registrant as ...

NeueHealth, Inc. Q4 2023 Earnings Conference Call March 6, 2024 12:00 AM ET Company Participants Emily Lombardi - Investor Relations Mike Mikan - President and CEO Jay Matushak - CFO Tomas Orozco - Executive Vice President Conference Call Participants Joshua Raskin - Nephron Research Operator Good morning. My name is Drew, and I'll be your conference operator today. At this time, I would like to welcome everyone to the NeueHealth Q4 2023 Earnings Conference Call. All lines have been placed on mute to preven ...

Financial Performance - NeueHealth reported a revenue of $1.2 billion for the full year 2023, representing a 55% increase year over year[2]. - Total revenue for the year ended December 31, 2023, was $1,160,802, an increase of 54.5% compared to $751,163 in 2022[15]. - Capitated revenue for Q4 2023 reached $60,091, up 78.8% from $33,609 in Q4 2022, while ACO REACH revenue increased to $219,659, a 16.4% rise from $188,652[15]. - The net loss attributable to NeueHealth, Inc. common shareholders for the year was $1,200,599, compared to a loss of $1,495,231 in 2022, reflecting a 19.7% improvement[15]. - For the three months ended December 31, 2023, the net loss was $460,572 thousand, compared to a net loss of $657,792 thousand for the same period in 2022[25]. - Adjusted EBITDA for the same period was $(10,356) thousand, an improvement from $(22,247) thousand in Q4 2022[25]. Revenue Projections - For 2024, NeueHealth expects Enterprise Adjusted EBITDA to be between $15 million and $25 million[9]. - NeueCare Revenue is projected to be between $310 million and $320 million, while NeueSolutions Revenue is expected to be between $690 million and $700 million[9]. Operating Costs and Expenses - The Enterprise Adjusted Operating Cost Ratio is anticipated to be between 15% and 16%[9]. - Total operating expenses for the year were $1,737,798, a significant increase from $1,119,919 in 2022, primarily driven by medical costs of $996,582[15]. - The Operating Cost Ratio decreased to 22.3% in Q4 2023 from 40.9% in Q4 2022, indicating improved cost efficiency[26]. - The Adjusted Operating Cost Ratio for Q4 2023 was 16.1%, down from 26.6% in Q4 2022[26]. Assets and Cash Flow - Cash and cash equivalents decreased to $87,299 thousand as of December 31, 2023, down from $217,006 thousand in 2022[13]. - Total assets decreased to $1,225,480 thousand as of December 31, 2023, compared to $4,665,052 thousand in 2022[13]. - Cash used in operating activities for the year was $(2,726,546), a significant decline from cash provided of $234,466 in 2022[17]. Medical Costs and Liabilities - Medical costs payable increased to $157,903 thousand as of December 31, 2023, from $116,021 thousand in 2022[13]. Segment Performance - Total segment revenue for NeueCare in 2023 was $267,209, compared to $1,192,011 in 2022, indicating a shift in revenue dynamics[19]. - NeueSolutions reported total segment revenue of $899,383 for the year, up from $654,201 in 2022, reflecting growth in ACO REACH revenue[20]. - NeueCare reported a net income of $3,748 thousand for Q4 2023, a significant recovery from a net loss of $(149,985) thousand in Q4 2022[28]. - NeueSolutions experienced a net loss of $(14,632) thousand in Q4 2023, compared to a net loss of $(450) thousand in Q4 2022[29]. - The Adjusted EBITDA for NeueCare was $6,929 thousand for the year ended December 31, 2023, compared to $(146,870) thousand in 2022[28]. - The Adjusted EBITDA for NeueSolutions was $(5,919) thousand for Q4 2023, worsening from $(450) thousand in Q4 2022[29]. Impairments and Transaction Costs - The company reported a goodwill impairment of $401,385 for the year, which was not present in the previous year[15]. - The company incurred $4,363 thousand in transaction costs during Q4 2023, which are not reflective of ongoing business performance[30]. - The company expects to incur costs related to the bankruptcy of an ACO REACH care partner, impacting financial results[30]. Strategic Developments - The company completed the sale of its California Medicare Advantage business, allowing it to focus on care delivery and provider enablement[2].

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR Commission File Number: 001-40537 BRIGHT HEALTH GROUP, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 47-4991 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40537 BRIGHT HEALTH GROUP, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 47-4991296 | ...

Bright Health Group, Inc. (BHG) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Stephen Hagan - Investor Relations Director Mike Mikan - President and CEO Cathy Smith - Chief Administrative Officer and CFO Conference Call Participants Operator Ladies and gentlemen, welcome to the Bright Health Group First Quarter 2023 Earnings Call. My name is Kelly, and I will be coordinating your call today. I will now hand you over to Stephen Hagan, Investor Relations Director to begin. Steph ...

| --- | --- | |-------------------------------------------------------------------|-------| | | | | | | | | | | Bright Health Group First Quarter 2023 – Earnings Presentation | | | May 9, 2023 | | Disclaimer 2 Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operation ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 BRIGHT HEALTH GROUP, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 47-4991296 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 8000 Norman Center Drive, Suite ...

Financial Compliance and Liquidity - As of September 30, 2022, the company was not in compliance with the total debt to capitalization ratio covenant of its Credit Agreement[239]. - The company breached the minimum liquidity covenant in Q1 of fiscal year 2023, requiring a minimum liquidity of $75 million until March 3, 2023, and $85 million thereafter during the Waiver Period[240]. - The company executed an amendment to the Credit Agreement on November 8, 2022, allowing it not to test the debt to capitalization ratio covenant until September 30, 2023[239]. - The company faces substantial doubt about its ability to continue as a going concern due to projected cash flows and liquidity requirements[241]. Healthcare Regulations and Compliance - The company is subject to various federal and state healthcare laws, including the federal Anti-Kickback Statute and the Stark Law, which impose significant compliance requirements and potential penalties for violations[254][255][268]. - Non-compliance with healthcare regulations could result in civil, criminal, and administrative penalties, including exclusion from government programs like Medicare, which could adversely affect the company's operations and financial condition[256][270]. - The company must comply with HIPAA and CCPA regulations regarding the handling of Personally Identifiable Information (PII) and Protected Health Information (PHI), with penalties for non-compliance reaching up to $7,500 per intentional violation under CCPA[257][263]. - The company faces increased scrutiny and potential litigation related to its risk adjustment practices and relationships with providers, particularly under the federal False Claims Act (FCA)[254][270]. - The corporate practice of medicine laws in various states may restrict the company's business operations, potentially leading to civil and criminal penalties if violated[268][269]. - The company anticipates ongoing regulatory changes related to privacy and cybersecurity, which may require modifications to its products and features[263]. - Legal proceedings and investigations related to healthcare fraud and compliance could impose significant costs and strain corporate resources[270]. - The company must maintain accurate and comprehensive privacy policies to avoid claims of deceptive practices, which could lead to governmental investigations and significant liabilities[265]. - Compliance with new health information standards could significantly impact the company's operations and incur substantial costs[264]. Medicare and Financial Impact - The CARES Act and related legislation authorized over $186 billion in funding for healthcare providers to reimburse for lost revenues and healthcare-related expenses due to COVID-19[246]. - The Medicare sequestration payment adjustment, which reduces payments to Medicare providers by 2%, was phased back in on July 1, 2022, and will increase to 3% in the last six months of fiscal year 2030[247]. - The company services approximately 125,000 MA consumers, primarily in California, with reimbursement rates based on published Medicare rates[250]. - Changes to the Medicare program, including administrative or legislative changes to reimbursement policies, could significantly impact the company's profitability and consumer satisfaction[250]. - The final impact of Medicare Advantage rates can vary from estimates, potentially leading to material adverse effects on the company's financial condition and cash flows[253]. Financial Reporting and Internal Controls - A material weakness in internal controls over financial reporting was identified for the year ended December 31, 2021, related to claims processed inaccurately by a third-party service provider[280]. - The company announced a new material weakness in Q4 2022 related to its decision to exit the Individual and Family Plans (IFP) business, which may impact its financial reporting[283]. - The company is enhancing its claims quality assurance procedures and data mining capabilities to address overpayment issues and improve claims payment accuracy[281]. - The company is undertaking steps to remediate identified material weaknesses, but there is no assurance that these measures will be sufficient to prevent future weaknesses[284]. Legal and Market Risks - The company is facing a pending putative securities class action lawsuit alleging materially false and misleading statements regarding its business and operations, which could adversely affect its stock price[273]. - The U.S. Department of Justice and the Office of Inspector General have increased scrutiny of healthcare payors, which may lead to investigations and potential penalties for the company[275]. - The company may be required to refund amounts paid and/or pay fines due to inspections, reviews, audits, and investigations, which could materially affect its business[277]. - Risk adjustment programs impact the revenue recognized for enrolled membership, and inaccuracies in documenting health conditions could lead to financial penalties or underpayment[286]. - The company estimates incurred but not reported (IBNR) claims using actuarial methods, and inaccuracies in these estimates could negatively impact reported results[287]. - The final rule from CMS regarding RADV audits may have potential adverse effects on the company's operating results and financial condition if implemented[276]. Stock and Market Performance - As of December 31, 2022, the company had outstanding net operating losses (NOLs) of approximately $5.8 billion, which are available to reduce future taxable income[291]. - Goodwill and intangible assets accounted for approximately 21.6% of total assets on the consolidated balance sheet as of December 31, 2022[293]. - The company received notice from the NYSE regarding non-compliance with continued listing standards due to the average closing price of its common stock being less than $1.00 per share over a consecutive 30 trading-day period[294]. - The company has a six-month period to regain compliance with the minimum share price requirement, which may involve a reverse stock split subject to stockholder approval[295]. - If the NYSE permanently delists the company's shares, it could negatively impact liquidity, market price, and the ability to raise equity financing[296]. - The trading price of the company's common stock has experienced significant volatility, which may continue in the future[297]. - The company does not intend to declare dividends on its common stock in the foreseeable future, with returns depending solely on stock price appreciation[301]. - The company has broad discretion in the application of net proceeds from capital raises, which may not necessarily increase profitability[303]. - Any conversion of the Preferred Stock into common stock would dilute the ownership interest of existing common stockholders[312]. - The company is authorized to issue up to 100,000,000 shares of preferred stock without stockholder approval, which may affect the value of common stock[314]. - Increased costs associated with being a publicly traded company may be material, including legal and compliance expenses due to regulations like SOX and Dodd-Frank[315]. - The company's earnings are exposed to financial market risk, particularly from changes in interest rates[504]. - A hypothetical 1% increase in interest rates could lead to a market value decrease of approximately $33.4 million in the company's portfolios[505].